An Phase III Study of Recombinant Anti-IL-17A Humanized Monoclonal Antibody in Chinese Participants With PsO

NCT06299982 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

750

Enrollment

INDUSTRY

Sponsor class

Conditions

Plaque Psoriasis Patients

Interventions

DRUG: 608 Q2W
DRUG: 608 Q4W

Sponsor

Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.